<div>This briefing discusses AI-enabled biological design and highlights related trends, opportunities and regulatory choices for the EU. AI-enabled biological design means using artificial intelligence to predict, design or modify proteins, peptides and the DNA or RNA that produce them. It has rapidly evolved over the past few years and is now in routine use across European biopharmaceutical research, industrial biotechnology and vaccine development.</div><br />Source : <a href="https://www.europarl.europa.eu/privacy-policy/en">© European Union, 2026 - EP</a>
European Parliament - SANT Subcommittee (Public Health) · September 22, 2026
AI-enabled biological design: trends, opportunities and regulatory choices for the European Union
Original title: Briefing - AI-enabled biological design - Trends, opportunities and regulatory choices for the European Union - PE 795.715 - Committee on the Environment, Public Health and Food Safety - Committee on Industry, Research and Energy - Committee on Public Health
Briefing on AI use in protein, peptide and nucleic acid design across biopharmaceutical research, industrial biotechnology and vaccine development, with regulatory implications for the EU.
Published by European Parliament - SANT Subcommittee (Public Health). HealthSignal links to the original document; the summary above is extracted from the source text.